European prescribing attitudes for rheumatoid arthritis post-ADACTA
Results from the ADACTA trial, which showed that Swiss drug major Roche’s (ROG: SIX) RoActemra (tocilizumab) is superior to AbbVie’s (NYSE: ABBV) Humira (adalimumab) as a monotherapy in biologics-naive rheumatoid arthritis (RA) patients (The Pharma Letter March 18), have resulted in a modest to substantial increase in prescribing of RoActemra.
RoActemra prescribing increased by 43% to 60% of surveyed rheumatologists across the EU5 (France, Germany, Italy, Spain and the UK), according to a new report from health care advisory firm Decision Resources. In addition, 22% to 44% of respondents consider RoActemra more effective than Bristol Myers Squibb’s Orencia (abatacept) or Roche’s MabThera (rituximab).
Importance of head-to-head data
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze